[1]Sung H,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.[2]Allemani C,et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018 Mar 17;391(10125):1023-1075.[3]Gaetan Devos,et al.Three-Year Oncological Outcomes of the Randomized Phase II Trial ARNEO: Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-Risk Prostate Cancer.EAU2024 #Abstract A0602[4]Giesen A,et al.Two-year Quality of Life (QoL) outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cance.EAU2024 #Abstract A0604[5]Pan J, et al. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study [J]. Urol Oncol, 2019, 37(12) : 991 -998. 本资料仅用于医学、科学交流,可能涉及尚未在中国获批的产品和适应症。Document Number:EM-154932Expiration Date:2025-4-11* 此文仅用于向医学人士提供科学信息,不代表本平台观点更多医疗资讯,点击“阅读原文”查看